Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis

Inclusion Criteria:

- Subjects with chronic moderate to severe plaque type psoriasis for at least 6 months
prior to randomization, including significant nail involvement, defined as Nail
Psoriasis Severity Index (NAPSI) score ≥16 AND number of fingernails involved ≥4 AND
Psoriasis Area and Severity Index (PASI) score ≥12 AND Body Surface Area (BSA) score
≥10%

- Candidates for systemic therapy, i.e. psoriasis inadequately controlled by topical
treatment (including super potent topical corticosteroids) and/or phototherapy and/or
previous systemic therapy

Exclusion Criteria:

- Forms of psoriasis other than chronic plaque type psoriasis (e.g., pustular psoriasis,
palmoplantar pustulosis, acrodermatitis of Hallopeau, erythrodermic and guttate
psoriasis)

- Drug-induced psoriasis (e.g. new onset or current exacerbation from β-blockers,
calcium channel inhibitors or lithium)

- Ongoing inflammatory skin diseases other than psoriasis or any other disease affecting
the fingernails which may potentially confound the evaluation of study treatment
effects

- Ongoing use of prohibited treatments (e.g. topical or systemic corticosteroids (CS),
UV therapy). Washout periods do apply

- Prior exposure to secukinumab (AIN457) or any other biological drug directly targeting
IL-17 or the IL-17 receptor

- Exposure to any investigational drugs within 4 weeks prior to study treatment
initiation or within a period of 5 half-lives of the investigational treatment,
whichever is longer

- History of hypersensitivity to constituents of the study treatment

- Other protocol-defined inclusion/exclusion criteria do apply